(MENAFN- EIN Presswire) Increasing prevalence of zoonotic diseases and occurrence of rare infectious diseases to boost the market in the coming times
Autogenous Vaccines Market Segmented By Bacterial Strain, Viral Strain in Livestock Farming Companies, Veterinary Research Institutes
NEW YORK CITY, NEW YORK , UNITED STATES, February 22, 2023 /einpresswire.com / -- Worldwide revenue from the autogenous vaccines market stands at US$ 129.6 Million in 2022, with the global Autogenous Vaccines market estimated to surge ahead at a CAGR of 5.4% to reach a revenue of US$ 231.6 Million by the end of 2033.
As assessed by Persistence Market Research, bacterial strain segment is expected to hold a largest market value of US$ 92.7 Million by 2023. Overall, autogenous vaccines market sales account for approximately 1.3% revenue share in the global veterinary vaccines market, which was valued at around US$ 9.9 Billion at the end of 2022.
Request For Free Sample Report of“Autogenous Vaccines Market”@
Animal vaccinations are a crucial component in managing animal health. It aids in immune system stimulation and protects animals from numerous bacterial and viral illnesses. For animal immunisation needs, autogenous vaccines are generally favoured. According to federal regulations, an autogenous vaccine is created using a bacterial or viral strain from the sick animal. Products made from these strains can only be marketed by veterinarian or farm owners from where they were isolated.
Companies
.Pfizer Inc.
.Sandoz International GMBH
.Eli Lily & Company
.Hospira Inc.
.Amgen, Inc.
.Biocon Ltd.
.Actavis, Inc.
.Cipla Ltd.
.Teva Pharmaceutical Industries, Ltd.
.Dr. Reddy's Laboratories Ltd.
.Celltrion, Inc.
.Stada Arzeimittel Ag
.Mylan, Inc.
.Wockhardt Ltd.
Due to their higher efficiency compared to viral strains, the need for autogenous vaccines made from bacterial strains has increased over time. Some of the most often employed bacterial strains to create autogenous bacterial vaccines include Salmonella, Staphylococcus, Haemophilus, and Mycoplasma. In the upcoming years, demand for autogenous bacterial vaccines is projected to increase due to rising rates of bacterial infections in animals, a preference for vaccinations over antibiotics, and greater financing and support for the elimination of animal diseases globally.
Buy Full Report Now @
Key Takeaways from Market Study
.By type of strain, bacterial autogenous vaccines are expected to contribute to more than 1/3 revenue share in the market.
.By end user, livestock farming companies will lead by acquiring over 45% of market share. This sector has witnessed the most adoption of autogenous vaccines as compared to other end users.
.Europe holds around half of the global market share.
.Key players are focused on expanding their product portfolios and expansion at regional levels through collaborations and acquisitions.
.COVID-19 outbreak in big economies is expected to negatively impact demand for autogenous vaccines owing to reduced healthcare center visits. Impact was also observed on vaccine production and transportation owing to travel restriction and lack of workforce at production centers.
.The market in Thailand is projected to be the fastest-growing in the Asia Pacific region, and will expand at a CAGR above 5% through 2031.
.The U.S. market holds a big portion of revenue, and its market share accounts for more than 90% in North America.
Competition Landscape
There are both worldwide and regional market players in the autogenous vaccines industry. Leading companies emphasize inorganic expansions as one of their primary growth strategies in order to maintain market competitiveness. Additionally, industry participants are working to increase their local and international reach through mergers and acquisitions.
Key instances include:
.In Jan 2020, Innoject Pro was a newly developed subcutaneous chick vaccination technology that was unveiled by Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, New Jersey, USA, and Automazioni VX Inc.
.In Sep 2020, at its French facility, Ceva Santé Animale tripled its ability to produce bacterial autogenous vaccines, especially for pigs and poultry.
Request Customization @
Key Segments Covered in Autogenous Vaccines Industry Research
Product:
.Bacterial Strain
.Virus Strain
End User:
.Veterinary Research Institutes
.Livestock Farming Companies
.Veterinary Clinics and Hospitals
Region:
.North America
.Latin America
.Europe
.South Asia
.East Asia
.Oceania
.Middle East & Africa
Check out more Premium studies published by Persistence Market Research
outsourced clinical trials & formulation market
active pharmaceutical ingredient market
Telemedicine Market –
Dental Implants Market -
Soft Tissue Repair Market -
Metagenomics Market -
Defibrillator Market -
Home Healthcare Market -
About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients' business needs.
Contact Us:
Persistence Market Research
United States
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales –
Atul Singh
PMR
+1 646-568-7751
email us here
Visit us on social media:
twitter
linkedin